Classification and mitigation of negative injection experiences with biologic medications
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Classification and mitigation of negative injection experiences with biologic medications
Authors
Keywords
-
Journal
Dermatologic Therapy
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-02-04
DOI
10.1111/dth.13240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
- (2019) Elsie Grace et al. Dermatology and Therapy
- Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience
- (2018) Paul Sator Therapeutic Advances in Chronic Disease
- Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
- (2017) Désirée van der Heijde et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial
- (2017) J.-P. Lacour et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry
- (2015) D. Choquette et al. JOURNAL OF RHEUMATOLOGY
- Effectiveness of External Cold and Vibration for Procedural Pain Relief During Peripheral Intravenous Cannulation in Pediatric Patients
- (2015) Nejla Canbulat et al. Pain Management Nursing
- The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range
- (2015) Nicolaas D. Vlieland et al. RHEUMATOLOGY
- Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
- (2015) Susan Bolge et al. Patient Preference and Adherence
- Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial
- (2014) T. Heise et al. DIABETES OBESITY & METABOLISM
- Occurrence of psoriatic plaques on previous adalimumab injection sites during disease relapse in a patient with pustular psoriasis
- (2014) Ting-Shun Wang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adverse reactions to biologic agents and their medical management
- (2014) Onur Boyman et al. Nature Reviews Rheumatology
- Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
- (2012) Arthur Kavanaugh et al. ARTHRITIS AND RHEUMATISM
- The complexity of adverse side-effects to biological agents
- (2012) François Aubin et al. Journal of Crohns & Colitis
- Patch testing in patients treated with systemic immunosuppression and cytokine inhibitors
- (2010) Jamie S. Wee et al. CONTACT DERMATITIS
- Adverse drug reactions to biologics
- (2010) Kathrin Scherer et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- The Effect of Needle Bevel Position on Pain for Subcutaneous Lidocaine Injection
- (2009) Keith Candiotti et al. Journal of PeriAnesthesia Nursing
- Recall injection-site reactions to etanercept in a patient with psoriasis
- (2008) E. Papadavid et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started